Medico Remedies Limited (MEDICO)

Loading page…

Medico Remedies Limited (MEDICO) · mywealthgrid

About

Medico Remedies Limited manufactures pharmaceuticals with a market cap of ₹367.44 Cr, operating in generics and specialty pharmaceuticals for India's domestic healthcare market. Jun 2026 revenue reached ₹69.4 Cr, marking 81% YoY growth, though operating margins have become volatile and earnings quality has deteriorated.

Face value: ₹2

Market cap

₹181 Cr

P/E

13.1×

P/B

2.4×

Dividend yield

ROE

19%

ROCE

28.7%

Debt / equity

0.25

OPM

8.3%

EPS (TTM)

₹1.7

Book value

₹9.1

52-week high

—

52-week low

Key insights

Company research notes and source-linked reviews

Key risks

Operating margins collapsed from 16.13% (Mar 2025) to 4.76% (Jun 2026)—verify whether cost inflation, product mix, or capacity constraints drove the fall and whether recovery is realistic
Promoter holds 61.38% with minimal institutional investment (0.08% FII, 0% DII)—verify governance protections and stock liquidity implications for public shareholders
Net profit fell to ₹2.52 Cr in Jun 2026 despite 81% YoY revenue growth, indicating cost pressures—verify COGS trends and pricing power in generics segment
Pharma sector faces price regulation and intense generic competition—verify the company's therapeutic focus, regulatory exposure, and competitive moat

Generated analysis · source review pending

Growth drivers

Revenue grew 81% YoY from ₹38.25 Cr (Jun 2025) to ₹69.4 Cr (Jun 2026)—verify whether growth is sustainable or contract-driven
Return on equity of 19.04% shows capital efficiency—verify whether margins can recover from 4.76% (Jun 2026) toward historical 16% levels (Mar 2025)
Debt-to-equity ratio of 0.25 provides financial flexibility for capacity investment—verify capex plans and acquisition appetite
Operating leverage potential if fixed costs are absorbed across higher volumes at stable or recovering margins

Generated analysis · source review pending

1,072 historical price candles were omitted because the exchange source has not been verified.

₹22.0+0.7%1Y

Quick read

rule-based

Pros

+High return on capital employed of 26.2%
+Profit CAGR of 21.9% over the last 3 years
+Comfortable interest coverage of 11×
+High promoter holding of 61.4% with no pledge

Cons

No red flags triggered.

Research score

Structured signal from quality, growth, valuation and momentum.

75/100

Business quality: 61
Growth: 82
Valuation: 82

Revenue & net profit

₹ crore, by fiscal year

RevenuePAT

Margins

% of revenue, by fiscal year

OPMPAT margin

Peers

Comparable companies from the narrowest available industry classification.

Screen this industry Compare top 5 side-by-side

Company	Mkt Cap	EV	Revenue	EBITDA	OPM	PAT	NPM	ROCE	ROE	WC Days
Torrent Pharmaceuticals LimitedTORNTPHARMTORNTPHARM	₹1,61,325 Cr	₹1,76,123 Cr	₹15,723 Cr	₹5,191 Cr	32.6%	₹2,181 Cr	15.3%	14.5%	27.1%	163
Zydus Lifesciences LimitedZYDUSLIFEZYDUSLIFE	₹1,14,284 Cr	₹1,26,053 Cr	₹28,592 Cr	₹8,316 Cr	31.2%	₹4,513 Cr	18.9%	23.4%	19.7%	212
Laurus Labs LimitedLAURUSLABSLAURUSLABS	₹1,07,176 Cr	₹1,09,573 Cr	₹7,270 Cr	₹2,034 Cr	26.1%	₹1,093 Cr	13.1%	21.3%	18.2%	263
Mankind Pharma LimitedMANKINDMANKIND	₹1,04,696 Cr	₹1,11,007 Cr	₹14,738 Cr	₹3,827 Cr	25.3%	₹2,068 Cr	13.6%	14.2%	12.5%	117
Aurobindo Pharma LimitedAUROPHARMAAUROPHARMA	₹97,389 Cr	₹1,05,065 Cr	₹34,935 Cr	₹7,085 Cr	20.3%	₹3,713 Cr	10.4%	14.7%	9.9%	252
Lupin LimitedLUPINLUPIN	₹92,866 Cr	₹98,777 Cr	₹29,967 Cr	₹9,538 Cr	31.5%	₹5,529 Cr	19.2%	34.2%	26.9%	181
Glenmark Pharmaceuticals LimitedGLENMARKGLENMARK	₹65,781 Cr	₹65,781 Cr	₹17,737 Cr	₹4,797 Cr	26.9%	₹1,496 Cr	8%	37.8%	0%	83
Alkem Laboratories LimitedALKEMALKEM	₹62,431 Cr	₹64,055 Cr	₹15,081 Cr	₹3,032 Cr	20.4%	₹2,158 Cr	16%	21.5%	17.8%	152
Biocon LimitedBIOCONBIOCON	₹60,413 Cr	₹75,238 Cr	₹17,321 Cr	₹3,536 Cr	20.4%	₹495 Cr	2.2%	3.9%	1.4%	85
Abbott India LimitedABBOTINDIAABBOTINDIA	₹56,901 Cr	—	₹4,310 Cr	₹921 Cr	27.3%	₹691 Cr	22.4%	44.1%	34.5%	110
Ipca Laboratories LimitedIPCALABIPCALAB	₹49,299 Cr	₹50,003 Cr	₹10,126 Cr	₹2,232 Cr	20.5%	₹1,310 Cr	12.3%	17.8%	15.2%	308
Gland Pharma LimitedGLANDGLAND	₹47,428 Cr	₹47,671 Cr	₹6,725 Cr	₹1,751 Cr	25.3%	₹1,129 Cr	16%	14.8%	10.5%	255

Loading peers…

Financials

Reported profit and loss, balance sheet, cash flow and growth history.

Annual Quarterly

Standalone figures · ₹ crore

₹ Cr	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
	121	140	145	151	206
COGS	87	105	110	108	151
Gross profit	34	36	35	43	55
	26	26	22	28	38
	7	10	13	15	17
OPM %	6.1%	6.9%	8.9%	9.9%	8.3%
Depreciation	2	3	3	3	3
Interest	1	1	1	1	2
	2	4	2	3	6
Profit before tax	6	10	11	14	18
Tax	2	3	3	3	5
Tax %	25.8%	28.3%	26.8%	25.3%	27.4%
	5	7	8	10	13
PAT margin %	4%	5.2%	5.7%	6.7%	6.4%
EPS (₹)	0.6	0.9	1	1.2	1.6
EPS adjusted (₹)	0.6	0.9	1	1.2	1.6
Annual report	Annual report for Mar 2022	Annual report for Mar 2023	Annual report for Mar 2024	Annual report for Mar 2025	—

₹ Cr	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Equity capital	4	17	17	17	17	17
Reserves	28	20	27	36	46	59
	15	11	10	8	15	19
	28	30	34	36	43	59
Total equity & liabilities	75	77	87	96	120	153
	15	18	20	20	21	20
CWIP	—	—	2	1	1	3
Investments	0	0	0	2	2	2
	60	59	66	73	96	129
Total assets	75	77	87	96	120	153

₹ Cr	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
	6	8	2	5	6
	-2	-7	-3	-3	-5
	-6	-2	-0	-1	-1
Net cash flow	-2	-0	-1	1	1
Free cash flow	-0	8	2	5	6
CFO / Operating profit %	80%	84.9%	18.9%	32.6%	34.5%

Compounded sales growth

7 years: —
5 years: —
3 years: 14%
1 year: 37%

Compounded profit growth

7 years: —
5 years: —
3 years: 22%
1 year: 30%

Return on equity

7 years: —
5 years: 16%
3 years: 17%
Last year: 17%

Loading financials…

Ratios

Annual operating, return, leverage and working-capital ratios.

Standalone figures

Ratio	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Margins
Gross margin %	27.9%	25.3%	24.2%	28.2%	26.7%
EBITDA margin %	6.1%	6.9%	8.9%	9.9%	8.3%
EBIT margin %	4.2%	4.9%	6.9%	7.9%	6.8%
PAT margin %	4%	5.2%	5.7%	6.7%	6.4%
Working capital
Receivable days	92	94	125	138	145
Inventory days	76	69	54	90	72
Payable days	113	108	105	117	119
NWC days	54	55	75	111	98
Leverage
Current ratio	1.51	1.55	1.72	1.7	1.66
Debt to EBITDA	1.45	1.02	0.62	0.98	1.11
Debt to equity	0.29	0.22	0.15	0.24	0.25
Interest coverage	10.8	14.5	14.8	12.6	11
Asset turnover	1.56	1.61	1.51	1.26	1.35
Return ratios
Return on assets %	6.2%	8.3%	8.6%	8.4%	8.6%
Return on capital employed %	18.2%	25.5%	24.5%	25.3%	28.7%
Return on equity %	13.1%	16.5%	15.8%	16.2%	17.4%

Derived from reported annual statements. ROCE uses EBIT over capital employed (total assets less current liabilities). Day counts average the opening and closing balance; receivables turn on revenue, inventory and payables on cost of goods sold.

Loading ratios…

Shareholding

Quarterly ownership, named holders, insider transactions and disclosed deals.

Quarterly Annual

Every quarter filed · % of equity

Holder (%)	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026
	73.34%	73.34%	73.34%	73.34%	73.34%	66.83%	63.79%	62.59%	61.38%	61.38%	61.38%	61.38%
	1.12%	1.29%	0.29%	0.23%	0.22%	0.39%	0.12%	0.07%	0.3%	0.49%	0.03%	0.08%
	0%	0%	0.74%	0.97%	0.97%	0.78%	0.01%	0.01%	0.01%	0%	0%	0%
Government	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%
	25.54%	25.37%	25.63%	25.46%	25.47%	32%	36.08%	37.33%	38.31%	38.13%	38.59%	38.54%
No. of shareholders	—	—	—	—	—	—	—	—	18,503	16,562	16,189	15,863

Promoter holding down 11.96 percentage points since Sep 2023.

80 deals · 26 Sept 2022 – 25 Sept 2026

Date	Client	Type	Venue	Side	Quantity	Price	Value
25 Sept 2026	SAVITRIBEN MAHENDRAKUMAR SHAH	Bulk	NSE	Sell	4,37,647	₹27.22	₹1.19 Cr
27 Mar 2026	RG HUF	Bulk	NSE	Sell	42,57,300	₹33.93	₹14.45 Cr
27 Mar 2026	R G FAMILY TRUST	Bulk	NSE	Buy	42,57,300	₹33.93	₹14.45 Cr
25 Mar 2026	RAVI GOYAL (HUF)	Bulk	NSE	Sell	14,00,000	₹37.67	₹5.27 Cr
25 Mar 2026	R G FAMILY TRUST	Bulk	NSE	Buy	14,00,000	₹37.67	₹5.27 Cr
23 Jan 2026	ALTIZEN VENTURES LLP	Bulk	NSE	Buy	8,65,452	₹54.00	₹4.67 Cr
23 Jan 2026	ALTIZEN VENTURES LLP	Bulk	NSE	Sell	7,06,950	₹52.69	₹3.72 Cr
23 Jan 2026	VISHAL MAHESH WAGHELA	Bulk	NSE	Buy	5,10,000	₹53.41	₹2.72 Cr
24 Sept 2025	ARYAMAN CAPITAL MARKETS LIMITED	Bulk	NSE	Sell	6,50,000	₹48.02	₹3.12 Cr
27 Jun 2025	PASHUPATI CAPITA SER PVT LTD	Bulk	NSE	Sell	12,05,985	₹41.50	₹5.00 Cr

1–10 of 80

1 / 8

Mr. HARESH KAPURLAL MEHTAExecutive Director-Chairperson related to Promoter
Mr. HARSHIT HARESH MEHTAExecutive Director-MD
Mr. RISHIT HARESHBHAI MEHTAExecutive Director
Ms. RITA HARESH MEHTANon-Executive - Non Independent Director
Mr. DEEPAK MAGANLAL VEKARIANon-Executive - Independent Director
Mr. BHARAT NATHALAL RATHODNon-Executive - Independent Director
Mr. DEEPESH RAJESH SHAHNon-Executive - Independent Director
Mr. KUNAL TUSHAR VORANon-Executive - Independent Director
Mr. MAHESHKUMAR DARJIExecutive Director
Mr. ANUJ KISHORE MODYNon-Executive - Independent Director
Ms. Vidhi Ankit ShahCompany Secretary & Compliance Officer

Loading shareholding…

F&O

Current futures and options contracts with compact option-chain pages.

Not in the F&O segment

Only about 210 stocks have listed futures and options. Contracts appear here for those, refreshed after each close.

Loading f&o…

Fund holders

Mutual-fund schemes that disclosed a holding in the company.

No fund holdings on record

No scheme among the 32 fund houses on record reported a position in Medico Remedies Limited. Portfolios are published monthly by each AMC; coverage is still partial.

Loading fund holders…

Documents

Annual reports, exchange filings, offer documents, ratings and earnings-call material.

Announcements

Please find enclosed.29 Sept 2026 · General
The Exchange has sought clarification from Medico Remedies Ltd on September 29, 2026 with reference to significant movement in price, in order to ensure that investors have latest relevant ....29 Sept 2026 · Clarification
Please find enclosed, Intimation for Closure of Trading Window29 Sept 2026 · Closure of Trading Window
Please Find Enclosed Proceedings of 32nd AGM

Loading documents…

Events

Upcoming dates and the company’s corporate-action history.

1

Board meeting to consider results13 Aug 2026

1

Face value ₹10 → ₹216 Mar 2023 · ex-date

1

Bonus 3:116 Nov 2021 · ex-date

Loading events…

Announcements

Latest exchange announcements, filings and downloadable documents.

1 month 3 months 6 months 1 year All

11 announcementsExport CSV

29 Sept 2026, 6:39 pmCompany Update

Clarification On Price Movement

General PDF

Loading announcements…

Ratio	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Margins
Gross margin %	27.9%	25.3%	24.2%	28.2%	26.7%
EBITDA margin %	6.1%	6.9%	8.9%	9.9%	8.3%
EBIT margin %	4.2%	4.9%	6.9%	7.9%	6.8%
PAT margin %	4%	5.2%	5.7%	6.7%	6.4%
Working capital
Receivable days	92	94	125	138	145
Inventory days	76	69	54	90	72
Payable days	113	108	105	117	119
NWC days	54	55	75	111	98
Leverage
Current ratio	1.51	1.55	1.72	1.7	1.66
Debt to EBITDA	1.45	1.02	0.62	0.98	1.11
Debt to equity	0.29	0.22	0.15	0.24	0.25
Interest coverage	10.8	14.5	14.8	12.6	11
Asset turnover	1.56	1.61	1.51	1.26	1.35
Return ratios
Return on assets %	6.2%	8.3%	8.6%	8.4%	8.6%
Return on capital employed %	18.2%	25.5%	24.5%	25.3%	28.7%
Return on equity %	13.1%	16.5%	15.8%	16.2%	17.4%

Date	Category	Subject	Filing
29 Sept 2026, 6:39 pm	Company Update General	Clarification On Price Movement	PDF
29 Sept 2026, 5:45 pm	Company Update Clarification	Clarification sought from Medico Remedies Ltd	—
29 Sept 2026, 4:19 pm	Insider Trading / SAST Closure of Trading Window	Closure of Trading Window	PDF
22 Sept 2026, 4:54 pm	AGM/EGM AGM	Shareholder Meeting / Postal Ballot-Outcome of AGM	PDF
29 Aug 2026, 4:22 pm	Others Reg. 34 (1) Annual Report	Reg. 34 (1) Annual Report.	PDF
29 Aug 2026, 4:17 pm	Corp. Action Book Closure	Intimation Of Book Closure Date Pursuant To Regulation 42 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015.	PDF
29 Aug 2026, 4:13 pm	AGM/EGM AGM	Submission Of Annual Report For The Financial Year 2025-26 Along With The Notice Of The 32Nd Annual General Meeting	PDF
17 Aug 2026, 4:47 pm	Company Update General	Clarification On Price Movement	PDF

Medico Remedies Limited

About

Key insights

Key risks

Growth drivers

Quick read

Pros

Cons

Research score

Revenue & net profit

Margins

Peers

Financials

Profit & loss

Balance sheet

Cash flow

Compounded returns

Compounded sales growth

Compounded profit growth

Return on equity

Ratios

Ratio timeline

Shareholding

Quarterly record

Bulk & block deals

Board and management

F&O

Not in the F&O segment

Fund holders

No fund holdings on record

Documents

Announcements

Events

Board meetings1

Stock splits1

Bonus issues1

Announcements

Ratio timeline

Not in the F&O segment

No fund holdings on record

Board meetings1

Stock splits1

Bonus issues1

Quarterly record

Bulk & block deals

Board and management

Announcements

Annual reports

Credit ratings

Profit & loss

Balance sheet

Cash flow

Compounded returns

Compounded sales growth

Compounded profit growth

Return on equity

1

1

1

1

1

1